NR4A2 and synucleinopathy: Given the association between reduced Nurr1 expression and these changes in dopaminergic neurons, beside anti-synucleinopathy therapy, increasing Nurr1 expression has been suggested as a promising therapeutic target for Parkinson disease [28].